NCT06105606|TerminatedDMCFDA Device
Study Stopped
Low accrual
Loading search results
Sponsor study identifier
interventional
3
1 country
1
Study Start
March 8, 2024
Actual (reported)Primary Completion
January 26, 2026
Actual (reported)Study Completion
January 26, 2026
Actual (reported)This research is being done to evaluate the feasibility of the AveCure Flexible Microwave destruction of tissue (Ablation) Probe for the treatment of malignant central airway obstruction using a thin, tube-like instrument with a light and a lens for viewing and removing tissue (bronchoscopic). The name of the intervention being used in this research study is: AveCure Flexible Microwave Ablation Probe (handheld, surgical device that delivers microwave energy via flexible probe tip)
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 26, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 5, 2023
Actual (reported)October 27, 2023
Actual (reported)March 8, 2024
Actual (reported)January 26, 2026
Actual (reported)January 26, 2026
Actual (reported)Feasibility Failure Rate (FFR)
Feasibility of the AveCure microwave technology to ablate a target malignant central and lobar airway lesions causing \> 50% obstruction, defined as at least 9/10 of the planned ablations (90%) successfully performed bronchoscopically according to the study protocol
6 months
6-month airway patency rate
6 months
Grade 3-5 Treatment-related Toxicity Rate
Adverse events evaluated 1, 3 and 6 month after procedure.
Airway Obstruction (AO) Rate
CT scan at 1, 3, 6 and 12 months after procedure
Change in Subjective Perception of Dyspnea
Assessed 1, 3, 6 and 12 months after procedure.
Number and type of additional tools that are used during bronchoscopy.
Index procedure only (at ablation).
Participants will undergo study procedures as follows: * Baseline assessments * Hospital admission for bronchoscopy under general anesthesia and microwave ablation via standard of care. * Participants will be followed at 1, 3, and 6 months post-procedure.
Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Jason Beattie, MD
Beth Israel Deaconess Medical Center
3 participants (actual enrollment reported by the registry).
First Submitted
July 5, 2023
First Posted
October 27, 2023
Study Start
March 8, 2024
Actual (reported)Effectiveness Of Apneic Oxygenation During Induction Of General Anesthesia In Children
Contact the study team to confirm eligibility.
Primary Completion
January 26, 2026
Actual (reported)Study Completion
January 26, 2026
Actual (reported)Last Updated
April 13, 2026
Record last verified: 2026-04
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: